98 related articles for article (PubMed ID: 20417304)
21. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
22. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
23. Optimal Affinity Enhancement by a Conserved Flexible Linker Controls p53 Mimicry in MdmX.
Borcherds W; Becker A; Chen L; Chen J; Chemes LB; Daughdrill GW
Biophys J; 2017 May; 112(10):2038-2042. PubMed ID: 28487147
[TBL] [Abstract][Full Text] [Related]
24. Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53-Mdm4.
Hoppmann C; Wang L
Chem Commun (Camb); 2016 Apr; 52(29):5140-3. PubMed ID: 26996321
[TBL] [Abstract][Full Text] [Related]
25. Structure of human MDM4 N-terminal domain bound to a single-domain antibody.
Yu GW; Vaysburd M; Allen MD; Settanni G; Fersht AR
J Mol Biol; 2009 Feb; 385(5):1578-89. PubMed ID: 19084022
[TBL] [Abstract][Full Text] [Related]
26. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Gerhart SV; Kellner WA; Thompson C; Pappalardi MB; Zhang XP; Montes de Oca R; Penebre E; Duncan K; Boriack-Sjodin A; Le B; Majer C; McCabe MT; Carpenter C; Johnson N; Kruger RG; Barbash O
Sci Rep; 2018 Jun; 8(1):9711. PubMed ID: 29946150
[TBL] [Abstract][Full Text] [Related]
27. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.
Xiong S; Pant V; Zhang Y; Aryal NK; You MJ; Kusewitt D; Lozano G
J Pathol; 2017 Mar; 241(4):501-510. PubMed ID: 27925213
[TBL] [Abstract][Full Text] [Related]
28. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Liu T; Zhang H; Yi S; Gu L; Zhou M
Mol Oncol; 2019 May; 13(5):1047-1058. PubMed ID: 30672125
[TBL] [Abstract][Full Text] [Related]
29. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.
Togashi K; Okada M; Suzuki S; Sanomachi T; Seino S; Yamamoto M; Yamashita H; Kitanaka C
Anticancer Res; 2020 Sep; 40(9):4961-4968. PubMed ID: 32878784
[TBL] [Abstract][Full Text] [Related]
31. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.
Dewaele M; Tabaglio T; Willekens K; Bezzi M; Teo SX; Low DH; Koh CM; Rambow F; Fiers M; Rogiers A; Radaelli E; Al-Haddawi M; Tan SY; Hermans E; Amant F; Yan H; Lakshmanan M; Koumar RC; Lim ST; Derheimer FA; Campbell RM; Bonday Z; Tergaonkar V; Shackleton M; Blattner C; Marine JC; Guccione E
J Clin Invest; 2016 Jan; 126(1):68-84. PubMed ID: 26595814
[TBL] [Abstract][Full Text] [Related]
32. Mdm4: don't judge an isoform by its mRNA levels!
Bardot B; Toledo F
Aging (Albany NY); 2015 Oct; 7(10):744-5. PubMed ID: 26525060
[No Abstract] [Full Text] [Related]
33. MDM4: What do we know about the association between its polymorphisms and cancer?
Almeida GM; Castilho AC; Adamoski D; Braun-Prado K
Med Oncol; 2022 Dec; 40(1):61. PubMed ID: 36566308
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis.
Mei Q; Yang Z; Xiang Z; Zuo H; Zhou Z; Dong X; Zhang L; Song W; Wang Y; Hu Q; Zhou Y; Qu J
Theranostics; 2023; 13(9):2787-2799. PubMed ID: 37284444
[TBL] [Abstract][Full Text] [Related]
35. MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.
Liu J; Yang J; Pan Q; Wang X; Wang X; Chen H; Zheng X; Huang Q
Eur J Med Res; 2024 Jan; 29(1):79. PubMed ID: 38281029
[TBL] [Abstract][Full Text] [Related]
36. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities.
Valentin-Vega YA; Box N; Terzian T; Lozano G
Differentiation; 2009 Jun; 77(5):442-9. PubMed ID: 19371999
[TBL] [Abstract][Full Text] [Related]
37. The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.
Fierabracci A; Pellegrino M
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27897991
[TBL] [Abstract][Full Text] [Related]
38. MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Wu J; Lu G; Wang X
Am J Cancer Res; 2021; 11(12):5864-5880. PubMed ID: 35018230
[TBL] [Abstract][Full Text] [Related]
39. CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.
Togashi K; Suzuki S; Mitobe Y; Nakagawa-Saito Y; Sugai A; Takenouchi S; Sugimoto M; Kitanaka C; Okada M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201546
[TBL] [Abstract][Full Text] [Related]
40. Targeting MDM4 Splicing in Cancers.
Bardot B; Toledo F
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28230750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
